louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06054867: PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
Official title: PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Localized Prostate Cancer
Keywords: AQUABEAM
Aquablation
Aquablation therapy
Robotic Waterjet Treatment
RWT
Prostate cancer
Lead sponsor: PROCEPT BioRobotics
Sponsor class: INDUSTRY
First posted: 2023-09-26
Enrollment: 22
Sex: MALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in treating patients with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.


Eligibility criteria: Inclusion Criteria:

* Clinical Stage ≤ T2c
* PSA ≤ 20 ng/ml
* Prostate volume ≥ 30 ml
* Grade Group (GG) 1 or 2: If GG 1: ≥ 3 cores positive for cancer. Note, multiple positive from any MRI targeted lesion will be considered as a single positive core.

Exclusion Criteria:

* Any prior or current treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation or chemotherapy.
* Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 12 months.
* Radiographically suspicious lymph node involvement confirmed with biopsy or PET scan.
* Evidence of bone metastasis.
* Evidence of extracapsular involvement.
* Evidence of seminal vesicle invasion on DRE or MRI read as "definite", "probable" or "consistent with"
* Any condition or history of illness or surgery that may pose an additional risk to men undergoing the Aquablation procedure.

Primary outcomes:
measure: Proportion of participants who experience a serious device-related adverse event within 12 months following the study treatment.
timeFrame: 12 months post-treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California, Institute of Urology
state: California
city: Glenview
country: United States
facility: NorthShore University HealthSystem
state: Illinois
city: New York
country: United States
facility: NYU Grossman School of Medicine
state: New York
Study officials:
References:
Clinical trial NCT03174067: Buprenorphine in the Emergency Department
Official title: Buprenorphine in the Emergency Department: Buprenorphine Versus Clonidine for Opioid Withdrawal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Opioid Withdrawal
Opioid-use Disorder
Keywords: buprenorphine
emergency department
Lead sponsor: St. Joseph's Health Centre Toronto
Sponsor class: OTHER
First posted: 2017-06-02
Enrollment: 26
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal. Primary treatment outcome is attendance at a rapid access addiction medicine clinic within a few days of emergency room presentation. Secondary treatment outcome is treatment status with respect to opioid agonist treatment at one month post emergency room visit.


Eligibility criteria: Inclusion Criteria:

1. Presenting to the ED in opioid withdrawal or soon to be in withdrawal
2. Minimum age 16
3. English speaking
4. Active phone number
5. Ontario Health Insurance Program card

Exclusion Criteria:

1. Pregnant
2. Currently enrolled in a methadone or buprenorphine maintenance
3. Benzodiazepine addiction (or taking \>50mg of valium equivalent/day)
4. Acute hepatitis or liver failure

Primary outcomes:
measure: Number of participants attending the rapid access clinic
timeFrame: 2-5 days
Secondary outcomes:
measure: Number of participants who are on opioid agonist treatment
timeFrame: 30 days
Other outcomes:
Locations:
Study officials:
affiliation: University of Toronto
name: Anita Srivastava, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Srivastava A, Kahan M, Njoroge I, Sommer LZ. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Can Fam Physician. 2019 May;65(5):e214-e220.
Clinical trial NCT07018167: Impact of Door-to-Needle Time on Stroke Outcomes at Gonesse Hospital
Official title: Impact of Door-to-Needle Time on Stroke Outcomes at Gonesse Hospital
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Stroke
Ischemic Attack, Transient
Cerebral Infarction
Thrombolytic Therapy
Treatment Outcome
Lead sponsor: Centre Hospitalier de Gonesse
Sponsor class: OTHER
First posted: 2025-06-12
Enrollment: 61
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will consist of adult patients (aged 18 and over) admitted to the Gonesse Hospital for acute ischemic stroke. All participants must have received intravenous thrombolysis (r-tPA) initiated at the hospital during the 3-month study period. Only patients with complete clinical and time-tracking data enabling the calculation of Door-to-Needle Time will be included.

Brief summary: This study looks at how quickly stroke patients receive treatment after arriving at Gonesse Hospital and whether this affects their recovery. Researchers will measure the time between a patient's arrival and the start of clot-busting treatment (called Door-to-Needle Time), as well as the time from symptom onset to hospital arrival (Home-Time). The goal is to see if treatment delays impact recovery, and to find ways to improve stroke care in the hospital.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18 years or older
* Confirmed diagnosis of acute ischemic stroke on imaging
* Initial acute stroke care provided at Gonesse Hospital during the study period (3 months)
* Intravenous thrombolysis (r-tPA) initiated at the hospital
* Availability of clinical and timing data to calculate Door-to-Needle Time (DNT)

Exclusion Criteria:

* Patients with hemorrhagic stroke or subarachnoid hemorrhage (SAH)
* Thrombolysis initiated before hospital arrival
* Missing, incomplete, or unusable timing data for DNT calculation

Primary outcomes:
measure: Time (in minutes) from hospital arrival to thrombolysis (Door-to-Needle Time).
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Gonesse
country: France
facility: France
Study officials:
References:
Clinical trial NCT01851967: Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans
Official title: Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Major Depressive Disorder
Keywords: Major depressive disorder
Cognitive behavioral therapy
Computerized CBT
Online CBT
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2013-05-13
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate efficacy and acceptability of the Chinese language version of MoodGYM as a therapeutic intervention in treating symptoms of depression in community dwelling Chinese Americans in the Boston area.

Hypothesis 1: Participants enrolled in MoodGYM will show a significant decrease in depressive symptoms after completion of the 5 modules.

Hypothesis 2: Participants enrolled in MoodGYM will show significantly improved dysfunctional thinking.

Hypothesis 3: Participants enrolled in MoodGym will rate this program as culturally acceptable.


Eligibility criteria: Inclusion Criteria:

* Resident of the US, but self-identified as Chinese origin
* At least 18 years of age
* Proficiency in Chinese, including the ability to read Chinese
* Access to computer and internet
* Scores \> 10 on the Chinese bilingual patient health questionnaire -9 item (PHQ-9)

Exclusion Criteria:

* Current ongoing psychiatric or psychological treatment
* Using illicit drugs or consumption \> 3 standard drinks in a day
* Currently experiencing a psychotic illness
* Past or current history of schizophrenia or bipolar disorder
* ECT during the last year
* Current active suicidal or self-injurious potential necessitating immediate face-to-face treatment

Primary outcomes:
measure: Change in Center for Epidemiologic Studies Depression Scale (CES-D)
timeFrame: Weeks 0, 6 (pre/post)
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital Depression Clinical and Research Program
state: Massachusetts
city: Beijing
country: China
facility: Ying Wang
Study officials:
References:
Clinical trial NCT04695067: The Influence of Central and Peripheral Fatigue on Sports Performance and Prevention of Sports Injury
Official title: Cooperation Between NTU and NTUS: Integrated Precision Approach to Improve Baseball Skills, Tactics and Competition Performance-The Influence of Central and Peripheral Fatigue on Sports Performance and Prevention of Sports Injury
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fatigue
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-01-05
Enrollment: 29
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: baseball pichers

Brief summary: This is an observational study that assess the baseball pitchers' fatigue status. The purpose of this study is to find the pitching mechanic change and the fatigue point to provide guidance for coaches to schedule training items . It is expected that earlier detect the pitchers' fatigue point could be able to prevent overuse injury caused by compensatory actions.

Detailed description: The expected outcomes of this study include providing more reliable scientific evidence of the effects of fatigue on baseball players' performance and movement control, which can help to improve muscle endurance and the quality of movement control. Moreover, fatigue that resulted from the prolonged practice can be reduced and recovered faster after exercise, as well as more understanding on the ideal pitching posture and compensatory action that caused by fatigue, providing a guideline for exercise training. This will not only help to prevent fatigue and reduce risk of injury, but also strengthen weak muscle groups and improve movement strategies before matches, as well as lengthen the time of being a baseball player.

Eligibility criteria: Inclusion Criteria:

* healthy baseball pitchers
* age between 18\~35 years old

Exclusion Criteria:

* surgery history in pitching arm
* Musculoskeletal disease
* Neuromuscular disease

Primary outcomes:
measure: heart rate variability (HRV)
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taiwan
Study officials:
affiliation: National Taiwan University
name: Wei-Li Hsu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06232967: PPIO-006 Primary Tumor Resection for IVa NSCLC
Official title: Long-term Outcome of Primary Tumor Resection in Non-Small-Cell Lung Cancer Patients With Dry Pleural Dissemination: A Multi-center Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-small-cell Lung Cancer (NSCLC)
Lead sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital of Chongqing Medical University
First posted: 2024-01-31
Enrollment: 223
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From January 2016 to December 2023, a total of 204 consecutive NSCLC patients with surgically confirmed DPD were collected retrospectively from three high-volume centers in China. Data were obtained by reviewing medical records.

Brief summary: The goal of this mutli-center observational study is toinvestigate the impact of primary tumor resection (PTR) on the long-term survival of patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination (DPD). The main question it aims to answer is: whether primary tumor resection improve long-term survival of NSCLC patients with dry pleural dissemination.

Detailed description: Non-small-cell lung cancer (NSCLC) patients with dry pleural dissemination have poor survival rates and are generally contraindicated for surgery. Previous single-center retrospective studies have suggested that these patients may benefit from primary tumor resection (PTR). However, the evidence supporting PTR is still limited, especially in the era of targeted therapy. This study aimed to investigate the impact of PTR on the long-term survival of patients with NSCLC and DPD.

Eligibility criteria: Inclusion Criteria:

(1) pathologically confirmed primary NSCLC with malignant pleural dissemination, (2) no preoperative treatment, (3) age 80 years or younger, (4) clinicopathologic data and follow-up results were complete.

Exclusion Criteria:

(1) pleural effusion, contralateral lung metastasis or distant metastasis revealed preoperatively, and (2) with a history of other malignant disease.

Primary outcomes:
measure: Disease-specific survival (DSS)
timeFrame: Up to 8 years
Secondary outcomes:
measure: Progression-free survival (PFS)
timeFrame: Up to 8 years
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Army Medical Center of the People's Liberation Army
state: Chongqing
Study officials:
affiliation: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
name: Wei Guo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00858767: Arabic Gum-Absorption Study
Official title: Comparison of Absorption and Efficacy of 3 Different Menaquinone-7 Delivery Systems; Casein Powder, Arabic Gum Powder, or Linseed Oil
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bioavailability
Keywords: vitamin K2
absorption
efficacy
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2009-03-10
Enrollment: 69
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Previous studies have indicated that menaquinone-7 (MK-7) is the most effective form of vitamin K. The Japanese soya product natto is one of the richest food sources of MK-7, but its taste is not appreciated by the Western society. For this reason, the active biological compound has been manufactured as enriched oil or casein (≈80% of proteins in cow's milk)-enriched powder. However, cow's milk allergy is the most common cause of food allergy affecting a minimum of 2-3% of infants. The investigators will therefore compare this protein-delivery system to an alternative delivery system (Arabic gum; 98% polysaccharides). To compare the difference between powder and oil as MK-7 delivery vehicle, the investigators will also test the efficacy of enriched linseed oil.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women aged between 20 and 40 y
* Normal body weight and height (BMI \<30 kg/m2)
* Stable body weight (weight gain or loss \<3 kg in past 3 mo)
* Caucasian race
* Written consent to take part in the study
* Low vitamin K status

Exclusion Criteria:

* (A history of) metabolic or gastrointestinal diseases
* Chronic degenerative and/or inflammatory diseases
* Abuse of drugs and/or alcohol
* Use of corticosteroids
* Use of oral anticoagulants
* (A history of) soy allergy
* Use of vitamin K-containing multivitamins or vitamin K supplements
* Anaemia
* Blood donation or participation in another study within one month before the study

Primary outcomes:
measure: serum level menaquinone-7
timeFrame: 8 weeks
Secondary outcomes:
measure: plasma level of biochemical markers carboxylated matrix-Gla protein, undercarboxylated matrix-Gla protein, carboxylated osteocalcin, undercarboxylated osteocalcin
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: VitaK BV /University of Maastricht
Study officials:
affiliation: VitaK /University of Maastricht
name: Cees Vermeer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06704867: High Flow Nasal Cannula Compared to Standard Oxygen for Endoscopic Ultrasound
Official title: High Flow Nasal Cannula Compared to Standard Oxygen Therapy for Endoscopic Ultrasound Procedure in High Risk Patients on Recovery Time and Procedural Conditions
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Endoscopic Ultrasound
Keywords: High Flow Nasal Cannula
High BMI
Oxygen
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Fisher and Paykel Healthcare
First posted: 2024-11-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of the study is to evaluate the use of high flow nasal cannula versus standard oxygen therapy for high-risk patients undergoing endoscopy procedures.

Detailed description: Patients with a higher BMI are at greater risk for lower oxygen levels which can delay the endoscopy procedure. This research is being conducted to find out if high risk patients will have a shorter recovery time and improved procedural conditions with a high flow nasal cannula versus standard oxygen therapy.

Eligibility criteria: Inclusion Criteria:

• All patients age 18 years and older who present to Gonda 2 procedural area for Endoscopic ultrasound (EUS) with or without endoscopy (EGD)/biopsy/tissue sampling. with BMI ≥ 35 kg/m2 (BMI within the past 6 months in electronic medical records or at current procedure) who are able to consent will be approached for potential enrollment.

Exclusion Criteria:

* Need for general anesthesia for the procedure instead of the standard monitored anesthesia care.
* Patients undergoing combined procedure: Therapeutic EUS/combined procedures including EUS/ERCP, EUS/colonoscopy
* Patients on home oxygen therapy, or the diagnosis of "severe COPD"
* Patients with existing tracheostomy
* Inpatients undergoing EUS
* Inability to consent
* Cognitive impairment
* Blocked nasal passages
* Trauma/previous surgery to the nasopharynx
* Irregularities of the nose, face, or airway such that HFNC cannot be properly fitted

Primary outcomes:
measure: Decrease recovery time
timeFrame: 4 hours
Secondary outcomes:
measure: Improve procedural conditions
timeFrame: 1 hour
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Bhargavi Gali, MD, MHA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03309267: Serratus Anterior Plane Block Versus Intercostal Block
Official title: Serratus Anterior Plane Block Versus Intercostal Block For Postoperative Analgesia Following Thoracotomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Postoperative
Keywords: pain, thoracotomy
Lead sponsor: Kahramanmaras Sutcu Imam University
Sponsor class: OTHER
First posted: 2017-10-13
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Thoracotomy Operation

Brief summary: Pain after thoracotomy is the most severe pain experienced by the patient. Good pain control after the operation provides comfortable respiration and reduces the development of chronic pain and complications.

we aimed to compare SAPB with IBregarding postoperative visual analog scale (VAS) scores and analgesic consumption in patients undergoing thoracotomy operation.

Detailed description: Patients who underwent thoracotomy operation in our hospital between May 2016 and June 2017 were examined. A retrospective evaluation was made of the data that was retrieved from the records of a total of 49 patients aged 18-75 years, ASA I-III, who were applied with Intercostal (IB) or Serratus anterior plane(SAPB) for a thoracotomy operation. The patient information was retrieved from the patient records and anesthesia block forms. The data were examined in respect of age, sex, height, weight, ASA, operation type, operating time, the amount of postoperative analgesic consumption, VAS at 1.,2.,4.,6.,12.,24. hours and complications (atelectasis, nausea, vomiting, hypotension and bradycardia).

Statistical analysis was performed using the SPSS program for Mac, version 17.0 (SPSS,Chicago,IL). Descriptive statistics are presented as mean and SD, and as the number of cases (n) and the corresponding percentage (%) for nominal variables. T tests were performed for normally continuous variables. The Mann-Whitney U test was used for non-parametric variables. A value of p \< 0.05 was considered statistically significant.

Eligibility criteria: Inclusion Criteria:

1. Thoracotomy operation
2. a.Serratus anaterior plane block b.Intercostal block

Exclusion Criteria:

1. missing data
2. written consent
3. rethoracotomy

Primary outcomes:
measure: Postoperative analgesic consumption
timeFrame: up to 24 hour
Secondary outcomes:
measure: Visuel analog scala (VAS)
timeFrame: up to 24 hour
Other outcomes:
measure: Complications
timeFrame: Postoperative 1 week
Locations:
city: Kahramanmaraş
country: Turkey
facility: KahramanmarasSIU
Study officials:
affiliation: Kahramanmaras Sutcu Imam University
name: Gözen Öksüz
role: PRINCIPAL_INVESTIGATOR
References:
citation: Okmen K, Okmen BM. The efficacy of serratus anterior plane block in analgesia for thoracotomy: a retrospective study. J Anesth. 2017 Aug;31(4):579-585. doi: 10.1007/s00540-017-2364-9. Epub 2017 Apr 26.